Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Poultry packaging partnership extends beyond the tray

Safcol to build $80m food manufacturing facility in SA

Avocado supply chain handling training program partners with Woollies

Technology report — Muting in practice: when safety becomes a vulnerability

Why Class 0 Oil-Free Compressors Are Essential for the Food & Beverage Industry

Redesigning for decarbonisation: the shift towards electrified hydraulic power

A guide to a cost-effective SIS

NSW launches Local Jobs First Commission legislation

What if your machines could talk? Now they can: meet MYZEL by Pilz

EA warns skills shortages remain profession’s biggest challenge

Flux Marine Redefines Marine Propulsion Through Electrification

Australian industry won't hit net zero if organisations hoard their data

Manufacturers could be missing out on govt energy funding

From Vision to Impact: How Epson is turning environmental ambition into measurable action

The McCrometer FPI Mag for use in municipal and industrial markets